Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2014

View Archived Issues

Heptares achieves research milestone in antibody collaboration with MedImmune

Johnson & Johnson reports regulatory news of fourth quarter 2013

Identification of RNA transcription enzyme repressors as novel anticancer drugs

Dendrimer-enhanced docetaxel clinical trial to begin in patients with solid tumors

Amgen reports topline data from phase III GAUSS-2 trial

Kancera to develop a vaccine against ROR to prevent cancer relapse

BioLineRx receives FDA orphan drug designation for stem cell mobilization therapy

California Stem Cell submits phase II trial protocol to FDA for Ovapuldencel-T

Pfizer reports topline results from phase III study of ALO-02

CytRx begins phase II trial of aldoxorubicin for AIDS-related Kaposi's sarcoma

DiaGenic reports final results from exploratory study of blood test for Alzheimer's disease

MDxHealth and Teva Pharmaceuticals sign agreement to commercialize two cancer tests in Israel

Japanese researchers present novel GSK-3 inhibitors for cancer

Roche discloses new agents for HCV infection

FDA grants orphan drug status to Aeolus' drug candidate for treatment of acute radiation syndrome

Novel fatty acid synthase inhibitors patented by GlaxoSmithKline

Novel PCSK9 inhibitors designed by Cadila Healthcare for dyslipidemia

Isis Innovation divulges new RNA polymerase inhibitors for infections

Novartis to request re-examination of E.U. filing for serelaxin

EMA committee recommends approval of Xolair in new indication

Endo and BioDelivery report results from phase III trial of BEMA buprenorphine in chronic pain

Valeant completes acquisition of Solta Medical

KIF20A-derived peptide plus gemcitabine evaluated in pancreatic cancer trial

Previously identified RIP1 kinase inhibitor potentially useful for necroptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...